Genetic counselling implementation in dilated cardiomyopathy.

No Thumbnail Available

Authors

Verdonschot J.A.J.
van SpaendonckZwarts K.Y.
Hellebrekers D.M.E.I.
Asselbergs F.W.
Behr E.R.
Charron P.
Dawson D.
GarciaPavia P.
Haugaa K.H.
Jurcut R.

Contact

Issue Date

2026

Type

Article

Language

Keywords

Research Projects

Organizational Units

Journal Issue

Alternative Title

Abstract

Genetic testing has become an integral part of the diagnostic workup of patients with dilated cardiomyopathy (DCM). While the initial goal of genetic testing was to identify family members at risk, recent advances have now extended their relevance to clinical decision-making. Our knowledge of the genetic architecture of DCM has expanded significantly, promoting a shift from the monogenic dogma towards a broader polygenic spectrum. However, current genetic testing strategies still primarily rely on the model of monogenic inheritance with an incomplete penetrance. Large studies have shown a yield varying from 8% to 36% of genetic testing in patients with DCM, depending on aetiology or family history. Genetic testing is generally warranted for every patient with DCM where genetic results could have an impact on risk stratification, the prognosis or the treatment of the patient, or its family members with an opportunity for reassurance or early disease detection. There are various strategies for genetic testing including broad multigene panels, or more targeted panels limited to specific disease-associated genes. Identified variants are classified by genetic laboratories, where pathogenic or likely pathogenic variants often have actionable clinical implications. It is crucial to interpret these variants in the context of the individual patient considering the phenotype and other contributing factors. When the genetic results are consistent with the patients' broader phenotype, potential clinical implications may include decision for device therapy, recommendations for family screening, and reproductive options. A comprehensive approach to integrate genetic testing in the clinical care of patients with DCM is proposed. Copyright © The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.

Description

Citation

Publisher

License

Journal

European heart journal

Volume

Issue

PubMed ID

DOI

ISSN

EISSN

Collections